Hematologic Malignancy clinical trials

Explore recruiting hematologic malignancy clinical trials.

Recruiting hematologic malignancy studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Hematologic Malignancy trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Fecal Microbiota Transplantation in the prevention of complications after allogeneic hematopoietic stem cell transplantation for hematologic malignancy

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Long-term Follow-up Study of Subjects With Malignancies Treated With CRISPR CAR Cellular Therapies

Germany

Phase I and Phase II (Integrated)- Other EU CTIS Study details

IMPACT-AML: A RANDOMIZED PRAGMATIC CLINICAL TRIAL FOR RELAPSE OR REFRACTORY ACUTE MYELOID LEUKEMIA

Germany, Czechia, Italy, Lithuania, Spain, Portugal +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Long-Term Follow-up: Phase I/II clinical study to evaluate the safety and efficacy of the infusion of autologous CD34+ cells transduced with a lentiviral vector carrying the FANCA gene (orphan drug) in patients with Fanconi Anaemia Subtype A: FANCOLEN-I

Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

CASPER-ATG-IPC 2023-015 : Reinforced prophylaxis of GVH in elderly patients with haematological malignancies receiving haploidentical allogeneic hematopoietic stem cell transplantation: use of a low dose of post-allograft anti-lymphocytic serum.

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Safety, Tolerability and Feasibility of Treatment with GP120-activated Regulatory T cells (ATreg) Early After Haematopoietic Stem Cell Transplantation (HSCT) to Reduce the Incidence and Severity of Acute Graft vs Host Disease (GvHD)

Germany

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Hematologic Malignancy trials by city

Hematologic Malignancy in Toronto Hematologic Malignancy in Vancouver Hematologic Malignancy in Montreal Hematologic Malignancy in Calgary Hematologic Malignancy in Edmonton Hematologic Malignancy in Ottawa Hematologic Malignancy in Winnipeg Hematologic Malignancy in Quebec City Hematologic Malignancy in Hamilton Hematologic Malignancy in Kitchener Hematologic Malignancy in London Hematologic Malignancy in Halifax Hematologic Malignancy in New York Hematologic Malignancy in Los Angeles Hematologic Malignancy in Chicago Hematologic Malignancy in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease